Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Roots

Showing results (191-200 of 225) with videos related to

Pageof 23
Sort By:
Clinical Pharmacology and Therapeutics|April 17, 2009
Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteersS V Vormfelde, J Brockmöller, S Bauer, et al.
Clinical Pharmacology and Therapeutics|November 5, 1999
Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolismC Sachse, S Ruschen, M Dettling, et al.
Pharmacogenetics|January 14, 2000
Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery diseaseI Cascorbi, M Laule, P M Mrozikiewicz, et al.
Scandinavian Journal of Work, Environment & Health|October 1, 1996
Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, GermanyK Golka, V Prior, M Blaszkewicz, et al.
Cancer Research|February 17, 2000
Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant--463A of the myeloperoxidase geneI Cascorbi, S Henning, J Brockmöller, et al.
The Pharmacogenomics Journal|July 5, 2006
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplicationJ Kirchheiner, H Schmidt, M Tzvetkov, et al.
Klinische Wochenschrift|January 1, 1988
Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer riskI Roots, N Drakoulis, M Ploch, et al.
The Pharmacogenomics Journal|August 24, 2005
Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19R Timm, R Kaiser, J Lötsch, et al.
Diabetes, Obesity & Metabolism|October 28, 2010
Genetic variants of the insulin receptor substrate-1 are influencing the therapeutic efficacy of oral antidiabeticsA Seeringer, S Parmar, A Fischer, et al.
Transplantation|August 1, 1991
Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipientsU Kunzendorf, G Walz, J Brockmoeller, et al.
Pageof 23

Showing results (191-200 of 225) with videos related to

Sort By:
Pageof 23
Clinical Pharmacology and Therapeutics|April 17, 2009
Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteersS V Vormfelde, J Brockmöller, S Bauer, et al.
Clinical Pharmacology and Therapeutics|November 5, 1999
Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolismC Sachse, S Ruschen, M Dettling, et al.
Pharmacogenetics|January 14, 2000
Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery diseaseI Cascorbi, M Laule, P M Mrozikiewicz, et al.
Scandinavian Journal of Work, Environment & Health|October 1, 1996
Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, GermanyK Golka, V Prior, M Blaszkewicz, et al.
Cancer Research|February 17, 2000
Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant--463A of the myeloperoxidase geneI Cascorbi, S Henning, J Brockmöller, et al.
The Pharmacogenomics Journal|July 5, 2006
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplicationJ Kirchheiner, H Schmidt, M Tzvetkov, et al.
Klinische Wochenschrift|January 1, 1988
Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer riskI Roots, N Drakoulis, M Ploch, et al.
The Pharmacogenomics Journal|August 24, 2005
Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19R Timm, R Kaiser, J Lötsch, et al.
Diabetes, Obesity & Metabolism|October 28, 2010
Genetic variants of the insulin receptor substrate-1 are influencing the therapeutic efficacy of oral antidiabeticsA Seeringer, S Parmar, A Fischer, et al.
Transplantation|August 1, 1991
Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipientsU Kunzendorf, G Walz, J Brockmoeller, et al.
Pageof 23